Optimizing Care in Atopic Dermatitis: Advanced Practice Provider Insights on Biologic and Systemic Therapies - Episode 4

Systemic Therapies for AD

Published on: 

Expert advanced practice providers in dermatology talk about the different systemic and biologic therapies that are currently available and in development for AD.

This is a video synopsis/summary of a panel discussion involving Melodie Young, NP, and Andrea Nguyen, PA.

In this video transcript, the speakers discuss advancements in therapies for a complex dermatological disease, likely autoimmune-related. The conversation covers both traditional and newer treatment modalities.

The efficacy of recent therapies in controlling signs and symptoms, minimizing flares, and improving patient outcomes is highlighted. The overview includes systemic therapies such as oral agents, immunosuppressants, JAK (Janus kinase) inhibitors, systemic corticosteroids, and newer biologic agents.

The discussion extends to topical therapies, emphasizing updates not reliant on steroids, including topical calcine inhibitors and a topical JAK inhibitor. Developments towards once-a-day dosing for enhanced patient convenience are noted.

Systemic agents, including conventional dermatologic therapies and systemic corticosteroids, are explored. The recent FDA approval of oral JAK inhibitors and injectable biologics, primarily proteins and monoclonal antibodies requiring refrigeration, is discussed.

The conversation underscores the disease's complexity, noting that monotherapy often falls short in achieving disease control. Clinical trials, however, frequently mandate monotherapy, occasionally allowing topical corticosteroids in specific cases.

This summary provides insight into the dynamic landscape of therapies discussed in the video, encompassing traditional, topical, and systemic approaches for managing a challenging dermatological condition.

Video synopsis is AI-generated and reviewed by HCPLive editorial staff.